Stanford University, School of Medicine, Stanford, CA; Pacific Health Foundation, San Jose, CA.
Hepatology. 2011 Jun;53(6):1839-45. doi: 10.1002/hep.24308.
Studies of hepatitis B virus (HBV)/hepatitis C virus (HCV) dual infection are limited. Most are small, conducted outside the United States, and compare dual infection with HCV monoinfection. The goal of this study was to characterize HBV/HCV dual infection in a large multiethnic, matched, case-control study of dual-infected and HBV-monoinfected patients at two United States centers. Using an International Classification of Disease Version 9 electronic query and chart review, we identified 115 HBV/HCV dual-infected patients with serial HBV DNA, HCV RNA, and alanine aminotransferase (ALT) levels. As a control, 115 HBV-monoinfected patients were chosen randomly and matched with cases by age ±10 years, sex, Asian versus non-Asian ethnicity, and study site. Both groups had similar sex, ethnic, and age distributions (68% male, 83% Asian, age 52 ± 14 years). The median follow-up times were 33 and 38 months for the dual-infected and monoinfected groups, respectively. More monoinfected patients received HBV antiviral therapy than dual-infected patients (43% versus 24%; P = 0.002). No significant difference was detected between the proportion of monoinfected versus dual-infected patients with ALT above 40 U/L at presentation or during follow-up. Dual infection patients exhibited very little HBV/HCV codominance at baseline and throughout follow-up: patients had either HBV viremia with low or absent HCV RNA or detectable HCV RNA with low or absent HBV DNA. Asian ethnicity was predictive of HBV dominance after adjusting for sex, age, and baseline ALT elevation (odds ratio 7.35; P = 0.01).
HBV/HCV dual-infected and HBV-monoinfected patients had similar clinical characteristics. Asian ethnicity is a major independent predictor of HBV-dominant disease, and HCV dominance with undetectable HBV DNA is more common in non-Asian individuals. Larger studies are needed to further characterize the natural history of HBV/HCV dual infection in Asian and non-Asian individuals.
乙型肝炎病毒(HBV)/丙型肝炎病毒(HCV)双重感染的研究有限。大多数都是在美国以外进行的小规模研究,并且比较了双重感染与 HCV 单一感染。本研究的目的是在两个美国中心进行的大型多民族、匹配的双重感染和 HBV 单一感染患者的病例对照研究中描述 HBV/HCV 双重感染。使用国际疾病分类第 9 版电子查询和图表审查,我们确定了 115 例 HBV/HCV 双重感染患者,这些患者具有连续的 HBV DNA、HCV RNA 和丙氨酸氨基转移酶(ALT)水平。作为对照,随机选择了 115 例 HBV 单一感染患者,并通过年龄±10 岁、性别、亚洲人与非亚洲人种族和研究地点与病例匹配。两组的性别、种族和年龄分布相似(68%为男性,83%为亚洲人,年龄 52±14 岁)。双重感染组和单一感染组的中位随访时间分别为 33 个月和 38 个月。接受 HBV 抗病毒治疗的单一感染患者多于双重感染患者(43%对 24%;P=0.002)。在就诊时或随访期间,ALT 高于 40 U/L 的单一感染患者与双重感染患者的比例没有显著差异。双重感染患者在基线和整个随访期间均表现出很少的 HBV/HCV 共显性:患者要么有 HBV 病毒血症,伴有低或无 HCV RNA,要么有可检测到的 HCV RNA,伴有低或无 HBV DNA。在调整性别、年龄和基线 ALT 升高后,亚洲种族是 HBV 优势的主要独立预测因素(优势比 7.35;P=0.01)。
HBV/HCV 双重感染和 HBV 单一感染患者具有相似的临床特征。亚洲种族是 HBV 优势疾病的主要独立预测因素,在非亚洲人群中,HCV 优势且 HBV DNA 不可检测更为常见。需要更大的研究来进一步描述亚洲和非亚洲人群中 HBV/HCV 双重感染的自然史。